EVO

Expands Just – Evotec Biologics partner-enablement and technology licensing model for proprietary continuous manufacturing platform Enables deployment of continuous manufacturing platform in partner-owned facilities to support higher productivity and flexibility compared with fed-batch technology biologics manufacturing Modular manufacturing infrastructure, equipment and proprietary technology enable rapid and cost-efficient increase in capacity for biologics manufacturing SEATTLE and HAMBURG, Germany, June 30, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the expansion of its Just – Evotec Biologics services with J.TRAIN, a new offering that enables biopharmaceutical companies to deploy Evotec's proprietary continuous manufacturing technology directly within their own facilities on a turnkey basis. J.TRAIN brings together prefabricated modular cleanrooms and industry-standard manufacturing equipment with Just – Evotec Biologics' cGMP-compliant process automation, designed to enable significantly faster and more cost-effective deployment than traditional manufacturing expansion.

11.06.2026 / 15:30 CET/CESTThe issuer is solely responsible for the content of this announcement. All agenda items adopted Dieter Weinand and Dr. Wolfgang Hofmann newly elected to the Supervisory Board Dieter Weinand appointed Chairman of the Supervisory Board Dr. Duncan McHale and Wesley Wheeler re‑elected to the Supervisory Board HAMBURG, Germany, June 11, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the results of its Annual General Meeting.

HAMBURG, DE / ACCESS Newswire / June 2, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Rui Wang as Executive Vice President, Head of Global In Silico and AI. Mr. Wang brings to Evotec more than 20 years of experience supporting global pharma and biotech organizations to embed scalable data, analytics & AI across R&D, drug development, manufacturing and supply chain functions.

Joint Evotec-Almirall team advances small molecule program to preclinical development significantly outperforming standard industry timelines Collaboration leverages Evotec's end-to-end integrated AI/ML-driven R&D capabilities and Almirall's dermatology expertise HAMBURG, DE / ACCESS Newswire / May 4, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the nomination of a small molecule preclinical development candidate (PDC) from its multi‑target drug discovery alliance in medical dermatology with Almirall S.A. The program is aimed at developing novel treatments for immune‑mediated inflammatory skin diseases with high unmet medical need.

Grants support discovery and development of novel drug candidates and evaluation and prioritization of advanced drug regimens for clinical testing New funding from the Gates Foundation extends Evotec's commitment to create more effective tuberculosis treatment regimens HAMBURG, GERMANY / ACCESS Newswire / April 30, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced that it has received two grants from the Gates Foundation for drug discovery and translation in tuberculosis (TB), following four earlier TB grants from the foundation, amounting to $4.9 million over 25 months and $5 million over 24 months. The new funding underscores Evotec's commitment to translating innovative science into impactful therapies addressing high-priority public health threats.

HAMBURG, DE / ACCESS Newswire / April 29, 2026 / Evotec SE (NASDAQ:EVO; Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first quarter 2026 and provide a business update on Wednesday, May 6, 2026. The conference call will be held in English.

Will play key role in strengthening cross-functional execution in support of global platform, scientific capabilities and partner delivery as well as the execution of the Horizon initiative Brings more than 20 years of international leadership experience across operations, transformation, strategy, supply, procurement and R&D integration HAMBURG, DE / ACCESS Newswire / April 15, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Dr. Ingrid Müller as Chief Operating Officer (COO). Dr. Müller will be joining Evotec's Management Board, effective May 1, 2026.

Evotec SE (EVO) Q4 2025 Earnings Call Transcript

Evotec said on Tuesday it would continue a dialogue with investor MAK Capital, ​which has published a list of ‌changes it wants the German biotech firm to make.

Strengthens Supervisory Board leadership to support Evotec's transformation, with a focus on commercial execution, strategic partnerships and profitability Industry veteran brings more than 30 years of global pharmaceutical industry leadership experience across senior management, commercial, operational and strategic roles HAMBURG, DE / ACCESS Newswire / April 7, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced that the Supervisory Board of Evotec SE has proposed the election of Dieter Weinand, M.S. as Chairman of the Supervisory Board at the June 11, 2026, Annual General Meeting.